针对严重急性脑损伤患者代理决策者的照护目标决策辅助工具试点随机临床试验
在2个美国三级神经ICU开展平行组、非盲、患者层面随机对照试点试验,将66名代理决策者按1:1分为决策辅助组与常规护理组,评估决策辅助工具的可行性、可接受性和感知有用性。决策辅助工具可行且被代理决策者接受,96%认为对决策有用;决策辅助组舒适照护决策有减少趋势,3个月死亡率较低,但需更大规模试验验证。
要点
- 决策辅助工具可行且被接受,96%代理决策者认为对决策有用。
- 决策辅助组舒适照护决策27% vs 常规组56%(p=0.1),有减少趋势。
- 决策辅助组3个月死亡率33% vs 常规组69%(p=0.05)。
核心结论
- 针对严重急性脑损伤患者的照护目标决策辅助工具在神经ICU中可行且被代理决策者接受,但需更大规模试验进一步验证。
研究设计与样本
- 在2个美国三级神经ICU开展平行组、非盲、患者层面随机对照试点试验。
- 共接触58名患者的83名代理决策者,最终纳入41名患者的66名代理决策者(同意率80%)。
- 代理决策者按1:1随机分配至决策辅助组或常规护理组,决策辅助组在临床医生-家属照护目标会议前接受纸质决策辅助工具。
主要发现
- 66名代理决策者中45名在3个月时仍在研究中(保留率68%)。
- 随机分配至干预组的33名代理决策者中,27名能够收到决策辅助工具,25名随后阅读(参与率93%)。
- 82%的代理决策者将决策辅助工具的可接受性评为良好或优秀(可接受性评分中位数2,IQR 2-3)。
- 决策辅助组舒适照护决策有减少趋势(27% vs 56%,p=0.1),代码状态改变较少(无改变73% vs 44%,p=0.02)。
- 3个月时决策辅助组死亡患者较少(33% vs 69%,p=0.05;格拉斯哥结局量表中位数3 vs 1,p=0.05)。
关键数值与推荐
- 无论接受何种干预,选择继续治疗的代理决策者在3个月时的心理结局显著更差。
临床怎么用
- 作者认为,支持神经ICU共享决策的照护目标决策辅助工具可行且被代理决策者接受,可开展更大规模试验。
- 作者认为,选择继续治疗的代理决策者需要额外的心理社会支持。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Breakdowns in clinician-family communication in neurologic intensive care units (neuroICUs) are common, particularly for goals-of-care decisions to continue or withdraw life-sustaining treatments while considering long-term prognoses. Shared decision-making interventions (decision aids [DAs]) may prevent this problem and increase patient-centered care, yet none are currently available. We assessed the feasibility, acceptability, and perceived usefulness of a DA for goals-of-care communication with surrogate decision makers for critically ill patients with severe acute brain injury (SABI) after hemispheric acute ischemic stroke, intracerebral hemorrhage, or traumatic brain injury. METHODS: We conducted a parallel-arm, unblinded, patient-level randomized, controlled pilot trial at 2 tertiary care US neuroICUs and randomized surrogate participants 1:1 to a tailored paper-based DA provided to surrogates before clinician-family goals-of-care meetings or usual care (no intervention before clinician-family meetings). The primary outcomes were feasibility of deploying the DA (recruitment, participation, and retention), acceptability, and perceived usefulness of the DA among surrogates. Exploratory outcomes included outcome of surrogate goals-of-care decision, code status changes during admission, patients' 3-month functional outcome, and surrogates' 3-month validated psychological outcomes. RESULTS: We approached 83 surrogates of 58 patients and enrolled 66 surrogates of 41 patients (80% consent rate). Of 66 surrogates, 45 remained in the study at 3 months (68% retention). Of the 33 surrogates randomized to intervention, 27 were able to receive the DA, and 25 subsequently read the DA (93% participation). Eighty-two percent rated the DA's acceptability as good or excellent (median acceptability score 2 [IQR 2-3]); 96% found it useful for goals-of-care decision making. In the DA group, there was a trend toward fewer comfort care decisions (27% vs 56%, p = 0.1) and fewer code status changes (no change, 73% vs 44%, p = 0.02). At 3 months, fewer patients in the DA group had died (33% vs 69%, p = 0.05; median Glasgow Outcome Scale 3 vs1, p = 0.05). Regardless of intervention, 3-month psychological outcomes were significantly worse among surrogates who had chosen continuation of care. DISCUSSION: A goals-of-care DA to support ICU shared decision making for patients with SABI is feasible to deploy and well perceived by surrogates. A larger trial is feasible to conduct, although surrogates who select continuation of care deserve additional psychosocial support. CLINICAL TRIALS REGISTRATION: Clinicaltrials.gov NCT03833375. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that the use of a DA explaining the goals-of-care decision and the treatment options is acceptable and useful to surrogates of incapacitated critically ill patients with ischemic stroke, intracerebral hemorrhage, or traumatic brain injury.
引用
- Muehlschlegel S, Goostrey K, Flahive J, et al. Pilot Randomized Clinical Trial of a Goals-of-Care Decision Aid for Surrogates of Patients With Severe Acute Brain Injury. Neurology. 2022. PMID: 35853748. doi:10.1212/WNL.0000000000200937
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。